Literature DB >> 18810687

Using animal models to develop new treatments for tuberculosis.

Eric Nuermberger1.   

Abstract

Animal models have an important role in the preclinical evaluation of new antituberculosis drug candidates. Although it does not recapitulate the clinicopathological manifestations of tuberculosis in humans, the mouse remains the best characterized and most economical animal model for experimental chemotherapy. Provided care is taken to optimize the experimental conditions, the mouse has produced reliable data on the bactericidal and sterilizing activity of existing antituberculosis drugs and informed numerous clinical trials. Still, other animal models, especially the guinea pig, may have utility as confirmatory, or even alternative, models under certain circumstances. This chapter reviews some of the important considerations when selecting an animal model and presents a model for the sequential evaluation of a new compound with promising antituberculosis activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18810687     DOI: 10.1055/s-0028-1085705

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  26 in total

1.  Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Authors:  Ian M Rosenthal; Rokeya Tasneen; Charles A Peloquin; Ming Zhang; Deepak Almeida; Khisimuzi E Mdluli; Petros C Karakousis; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Veronica Gruppo; Lisa K Woolhiser; Ian M Orme; Janet C Gilliland; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

3.  CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

Authors:  Payam Nahid; Jussi Saukkonen; William R Mac Kenzie; John L Johnson; Patrick P J Phillips; Janet Andersen; Erin Bliven-Sizemore; John T Belisle; W Henry Boom; Annie Luetkemeyer; Thomas B Campbell; Kathleen D Eisenach; Richard Hafner; Jeffrey L Lennox; Mamodikoe Makhene; Susan Swindells; M Elsa Villarino; Marc Weiner; Constance Benson; William Burman
Journal:  Am J Respir Crit Care Med       Date:  2011-10-15       Impact factor: 21.405

4.  A physiologically based pharmacokinetic model of rifampin in mice.

Authors:  Michael A Lyons; Brad Reisfeld; Raymond S H Yang; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

Review 5.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

6.  Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.

Authors:  Jamie Harper; Ciaran Skerry; Stephanie L Davis; Rokeya Tasneen; Mariah Weir; Igor Kramnik; William R Bishai; Martin G Pomper; Eric L Nuermberger; Sanjay K Jain
Journal:  J Infect Dis       Date:  2011-12-23       Impact factor: 5.226

7.  Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models.

Authors:  Si-Yang Li; Scott M Irwin; Paul J Converse; Khisi E Mdluli; Anne J Lenaerts; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

8.  Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.

Authors:  Zahoor Ahmad; Eric L Nuermberger; Rokeya Tasneen; Michael L Pinn; Kathy N Williams; Charles A Peloquin; Jacques H Grosset; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2010-01-31       Impact factor: 5.790

9.  Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.

Authors:  Zahoor Ahmad; Sandeep Tyagi; Austin Minkowski; Charles A Peloquin; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2013-07-01       Impact factor: 21.405

10.  Heme Oxygenase-1 Regulates Inflammation and Mycobacterial Survival in Human Macrophages during Mycobacterium tuberculosis Infection.

Authors:  Caitlyn R Scharn; Angela C Collins; Vidhya R Nair; Chelsea E Stamm; Denise K Marciano; Edward A Graviss; Michael U Shiloh
Journal:  J Immunol       Date:  2016-04-22       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.